Browse the evidence

Treatment of metabolic changes at menopause requires a flexible long-term strategy.

Practitioners should develop adaptable treatment plans for managing menopause-related metabolic changes.

SGLT-2 inhibitors and GLP-1 receptor agonists are effective in cardiovascular disease prevention among those with diabetes, heart failure, and chronic kidney disease.

Healthcare providers should consider these agents for patients with diabetes and related cardiovascular conditions.

GLP1-RA therapy appears safe and effective in patients with IBD.

GLP1-RA may be considered a treatment option for managing IBD.

GLP-1 receptor agonists have beneficial effects on atherosclerosis and cardiovascular disease.

Practitioners may consider GLP-1 receptor agonists as a treatment option for improving cardiovascular health in patients with obesity and type 2 diabetes.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

Current pharmacotherapy options for obesity include agents like liraglutide, semaglutide, and tirzepatide.

Practitioners should be aware of these specific pharmacotherapy options for treating obesity.

Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.

Practitioners should stay informed about emerging therapies that may enhance obesity treatment.

Male participants experienced greater effects than females (P < 0.001).

Practitioners should consider gender differences when designing resistance training programs.

GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.

These medications may be prioritized in treatment plans for T2D patients with obesity.

Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.

Practitioners should consider these new agonists for potentially better weight loss outcomes.

Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.

Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.

GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.

GLP-1 receptor agonists can be effectively used across different patient subgroups for BP management.

Tirzepatide is an efficacious and safe agent for the treatment of Type 2 Diabetes Mellitus (T2DM).

Practitioners can consider tirzepatide as a treatment option for managing T2DM.

Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.

Tirzepatide may offer better glycemic control than semaglutide in obese individuals.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT did not specifically improve menstrual frequency, overall menstrual frequency improved over time.

More participants became pregnant in the low-volume HIT (LV-HIT) group compared to the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

Preoperative semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair was associated with a lower incidence of any adverse events (11.0% vs 27.4%), severe adverse events (3.5% vs 10.5%), and minor adverse events (8.5% vs 22.0%) within 90 days post-surgery.

Practitioners may consider semaglutide as a beneficial preoperative intervention to reduce postoperative complications in diabetic patients.

Patients not using semaglutide had a greater odds ratio of experiencing any adverse events (3.65) and severe adverse events (3.62) compared to those using semaglutide.

Highlighting the importance of semaglutide in reducing the risk of complications may guide preoperative decisions.

Patients not using semaglutide had a higher 2-year rotator cuff retear rate (18.3% vs 12.5%) compared to those using semaglutide.

This finding suggests that semaglutide may improve long-term surgical outcomes in diabetic patients.

Gastric motor functions play a significant role in the development of satiation and satiety, impacting weight change.

Understanding gastric functions can help in designing effective weight loss interventions.

Pharmacological agents like liraglutide and dual agonists contribute to weight loss by retarding gastric emptying.

Incorporating GLP-1 agonists may enhance weight loss strategies.